The Aporia
Lim, D. (2026, September 25). Klomp wins over Democrat in bid to be No. 2 HHS official. Semafor. https://www.semafor.com/article/09/25/2026/klomp-wins-over-democrat-in-bid-to-be-no-2-hhs-official
Lim, David. “Klomp wins over Democrat in bid to be No. 2 HHS official.” Semafor, 25 Sept. 2026, https://www.semafor.com/article/09/25/2026/klomp-wins-over-democrat-in-bid-to-be-no-2-hhs-official.
Lim, David. “Klomp wins over Democrat in bid to be No. 2 HHS official.” Semafor, September 25, 2026. https://www.semafor.com/article/09/25/2026/klomp-wins-over-democrat-in-bid-to-be-no-2-hhs-official.
Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.
Chris Klomp, who served as President Donald Trump’s negotiator for lowering prescription drug prices through the “most-favored nation” (MFN) deals with pharmaceutical companies, has advanced to be the second-in-command at HHS, after being approved by the Senate Finance Committee on a vote of 15-12. Despite concerns from Democrats, Klomp was nominated in February and quickly rose through the ranks at HHS since Trump’s second term began in 2025. His role involved negotiating with 26 pharmaceutical firms to match U.S. prescription drug prices with those in developing countries. Notably, Democratic Senator Sheldon Whitehouse of Rhode Island joined Republicans to support Klomp's nomination, citing ongoing issues with Medicare reimbursement policies affecting his state.